Are Compounded GLP-1s Going Away? What FDA Changes Mean
- biobondlabs
- May 1
- 6 min read
Updated: May 2
Are Compounded GLP-1s Going Away? What FDA Changes Mean
For the past two years, compounded GLP-1 medications have filled a gap that many patients didn’t even realize existed until it suddenly affected them. Insurance denials, high retail prices, and supply shortages pushed thousands of people toward compounding pharmacies as an alternative.
Now, in late April 2026, the FDA took a significant step that’s raising a new question many patients are asking: are compounded GLP-1s going away?
Is that option about to disappear?
The answer is not as simple as yes or no. But the direction is becoming much clearer.
What the FDA Just Announced
On April 30, 2026, the FDA formally proposed that three widely used GLP-1 medications should not be eligible for large-scale compounding using bulk ingredients:
Semaglutide
Tirzepatide
Liraglutide
This proposal was published through the Federal Register and opens a public comment period through June 30, 2026 before any final rule is issued.
The action targets 503B outsourcing facilities, which are allowed to produce medications in large batches without patient-specific prescriptions.
The FDA’s position is direct.
There is no longer a recognized clinical need to compound these medications at scale because they are now considered commercially available in sufficient supply.
What “Compounded GLP-1s Going Away” Actually Means
This is where most of the confusion is happening.
When people hear restrictions are coming, many assume their prescription will suddenly stop being filled. That is not what this proposal does. But it does affect the system that made these medications widely accessible.
There are two very different types of compounding.
503B outsourcing facilities operate more like manufacturers. They produce medications in bulk and distribute them to clinics, telehealth platforms, hospitals, and medical practices. They do not typically serve individual patients directly.
503A traditional compounding pharmacies prepare medications for individual patients based on a prescription and dispense directly to that patient.
The April 2026 FDA proposal is focused on 503B facilities, not a complete shutdown of all compounding.
However, that distinction matters less than it seems.
503B facilities helped scale access during the shortage. Removing or limiting that pathway reduces overall supply flexibility, even if 503A compounding technically remains available.
Where Most Patients Actually Fit In
Many patients using compounded GLP-1 medications are getting them through telehealth platforms.
In simple terms, the process often looks like this:
•A provider evaluates the patient
•A prescription is written
•A pharmacy prepares the medication
•The medication is shipped directly to the patient
Some of these systems rely strictly on 503A pharmacies. Others rely on larger-scale supply chains tied to 503B facilities.
The FDA’s latest move directly impacts that second group.
What This Means for Telehealth Clinics
Telehealth providers may be affected depending on how they source medication.
Those relying on 503B production at scale may need to adjust or replace that supply.
Those operating through 503A pharmacies may continue, but under tighter scrutiny and stricter justification requirements.
That could lead to:
•Changes in pharmacy partners
•More restrictive prescribing
•Higher pricing
•Or removal of compounded options altogether
Do 503B Facilities Supply 503A Pharmacies?
Generally, no.
503A pharmacies source ingredients from FDA-registered suppliers, not from 503B outsourcing facilities.
503B facilities produce finished medications, not raw ingredients for smaller pharmacies.
This means the proposal does not directly remove the ingredient supply for 503A compounding, but it does remove a major high-volume production pathway.
Will Patients Be Forced Back to Traditional Healthcare?
Not immediately, but the system may move in that direction.
Telehealth will likely remain an option, but with fewer shortcuts, tighter rules, and less flexibility.
Some patients may eventually need to work more closely with primary care providers or specialists to maintain access.
The Real Takeaway
This is not a single switch being flipped.
It is a structural shift in how these medications are produced and distributed.
The FDA is not eliminating compounding entirely.
But it is targeting the high-volume pathways that made compounded GLP-1s widely accessible.
Why the FDA Is Tightening Control
The FDA is not making this move in isolation.
Throughout 2024 and 2025, the agency issued multiple warnings and updates tied to compounded GLP-1 products as supply conditions improved.
Several concerns were consistently identified:
•Non-approved salt forms
•Dosing inconsistencies and adverse events
•Shipping and storage concerns
•Products marketed outside licensed pharmacy channels
At the same time, the original justification for expanded compounding was tied to drug shortages.
By late 2025, the FDA signaled that supply had stabilized enough to remove that justification.
From their perspective, what began as a temporary solution became an ongoing workaround.
Why Cost Alone Doesn’t Justify Compounding
Many patients turned to compounded GLP-1s because the branded versions are expensive or not covered by insurance.
That is a real issue.
But under FDA policy, cost alone is not considered a valid clinical reason to compound a commercially available drug.
Even if a patient cannot afford the branded version, that does not legally justify routine compounding.
Will Adding Vitamins or “Custom Formulas” Keep Compounding Alive?
Some formulations combine GLP-1 medications with ingredients like vitamin B12 or pyridoxine.
The idea is that modifying the formula makes it permissible.
The FDA addressed this directly in the April 2026 proposal.
Adding ingredients does not automatically create a legitimate clinical need if those components can be prescribed separately.
What Patients Will Likely Notice Next
This will not feel immediate.
Most changes will happen gradually as the June 2026 comment period closes and final decisions are implemented.
Patients may notice:
Fewer telehealth options
More restrictive prescribing
Reduced availability
Pricing changes over time
What Could Happen to Pricing?
Pricing is one of the biggest concerns.
If large-scale compounding supply shrinks, upward pressure on pricing is likely.
During the shortage, compounded GLP-1s created a lower-cost cash-pay alternative. Many telehealth models were built around that gap.
If 503B production is restricted, some providers may need to shift sourcing, reduce availability, or raise prices to reflect higher costs.
Historically, when shortage-based compounding is reduced, cheaper alternatives become less available and patients are pushed back toward approved products, insurance coverage, or limited patient-specific compounding.
That does not mean pricing will spike overnight.
But the lowest-cost options may become harder to find.
There is one counterbalance.
Manufacturers have already introduced self-pay and savings programs in response to demand. These may provide a more stable option for some patients, though they come with eligibility limits and changing terms.
Patients paying fully out of pocket are the group most likely to feel the impact.
If Insurance Doesn’t Cover It, What Are the Options?
Many patients using compounded GLP-1s are doing so because insurance excludes coverage or sets strict criteria.
The FDA’s actions do not solve that problem.
Instead, they push patients toward:
Manufacturer savings programs
Insurance appeals
Clinically justified prescribing pathways
For some, those options will work.
For others, they may not.
The Bottom Line
Compounded GLP-1s are not disappearing overnight.
But the system that made them widely accessible is changing, and that shift accelerated with the FDA’s April 30, 2026 proposal.
Large-scale, routine compounding is being restricted.
If you are currently using a compounded GLP-1 medication, now is the time to understand your options and speak with your prescribing provider.
Because access may not vanish immediately, but it is becoming more limited.
Disclaimer
This content is for educational and informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any condition. Always consult a licensed healthcare provider regarding medications and treatment decisions. Individual responses may vary.
BioBond Labs™ products are intended for laboratory research use only and are not for human or veterinary consumption.
References
U.S. Food and Drug Administration. Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Proposed Rule. Federal Register. April 30, 2026.
U.S. Food and Drug Administration. FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide From 503B Bulks List. Press announcement. April 30, 2026.
U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. Updated 2025.
U.S. Food and Drug Administration. Outsourcing Facilities Under Section 503B of the FD&C Act. Updated 2025.
U.S. Food and Drug Administration. FDA’s Concerns With Unapproved GLP-1 Drugs Used for Weight Loss. Updated 2025.
U.S. Food and Drug Administration. Drug Shortages Database. Accessed 2026.
Gudeman J, Jozwiakowski M, Chollet J, Randell M. Potential risks of pharmacy compounding. JAMA. 2013;310(23):2473–2474.
Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740–756.
Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes Obes Metab. 2018;20(suppl 1):5–21.
ClinicalTrials.gov. Semaglutide and Tirzepatide clinical study listings. U.S. National Library of Medicine. Accessed 2026.
Pharmacy Times. FDA Moves to Permanently Close the Door on Compounded GLP-1s. Published 2026.
Reuters. U.S. FDA proposes excluding weight-loss drugs from compounding list. Published April 30, 2026.